Vimpat® (Epilepsy)

In August 2008, the European Commission approved Vimpat® (lacosamide) for the adjunctive treatment of partial onset seizures with or without secondary generalization in patients with epilepsy, age 16 and over.

Vimpat® solution for infusion is an alternative for patients when oral administration is temporarily not feasible.

In the US, Vimpat® is indicated for partial-onset seizures: tablets are indicated for adjunctive therapy in patients age 17 and over. Injection is indicated as short term replacement when oral administration is not feasible in these patients

SmPC Vimpat® (EU). Sourced from www.ema.europa.eu.